Participant Demographic and Baseline Drinking Factors Can Predict Alcohol Use Disorder Pharmacotherapy Clinical Trial Completion and Drinking Outcomes.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	Participant Demographic and Baseline Drinking Factors Can Predict Alcohol Use Disorder Pharmacotherapy Clinical Trial Completion and Drinking Outcomes.
Συγγραφείς:	Hoffman M; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA., Anton RF; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA., Aldridge A; RTI International, Research Triangle Park, Durham, North Carolina, USA.
Πηγή:	Alcohol, clinical & experimental research [Alcohol Clin Exp Res (Hoboken)] 2026 Apr; Vol. 50 (4), pp. e70288.
Τύπος έκδοσης:	Journal Article
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Wiley Periodicals Country of Publication: United States NLM ID: 9918609780906676 Publication Model: Print Cited Medium: Internet ISSN: 2993-7175 (Electronic) Linking ISSN: 29937175 NLM ISO Abbreviation: Alcohol Clin Exp Res (Hoboken) Subsets: MEDLINE
Imprint Name(s):	Original Publication: Hoboken, NJ : Wiley Periodicals, [2023]-
Ιατρικοί όροι (MeSH):	Alcoholism/drug therapy , Alcoholism/epidemiology , Alcohol Drinking/epidemiology , Alcohol Drinking/drug therapy , Alcohol Drinking/psychology , Randomized Controlled Trials as Topic/methods , Alcohol Deterrents*/therapeutic use, Humans ; Female ; Treatment Outcome ; Male ; Adult ; Middle Aged ; Alcohol Abstinence ; Demography
Περίληψη:	Background: Partially due to the complexity associated with conducting trials, there have been relatively few regulatory agency-approved medications for the treatment of alcohol use disorder (AUD). Heterogeneity of study samples, such as participant characteristics (including variation in alcohol consumption) as well as drinking efficacy endpoints, may lead to inconsistency in results and a potential increase in Type II errors. The aim of this study is to begin to fill in the knowledge gap of optimal clinical trial design by analyzing potential predictors of outcomes. Methods: Five federally funded and publicly available multisite randomized pharmacotherapy clinical trials for the treatment of AUD using similar methodologies to assess drinking outcomes were included. Three FDA-guided drinking efficacy outcomes were calculated for each study independently and combined: abstinence (no drinking days), no heavy drinking days, WHO 2+ risk drinking level (RDL) reduction as well as a measure of study participant completion. These outcomes were analyzed by logistic regression models including a variety of predictors within the full-study sample as well as among only participants treated with placebo. Results: The number of days abstinent prior to randomization was a strong positive predictor of all three predefined drinking outcomes. Further analysis indicated a cutoff of less than three to five abstinent days before randomization might be optimal. For the WHO 2+ RDL endpoint, those within the "high" or "very-high" risk categories were more likely to meet criteria for successful two or more risk level reductions than "medium" risk. Across various demographic variables, only age (older participants) was associated with better outcomes. Conclusions: These findings suggest that some important prestudy drinking characteristics (e.g., less abstinence and older age) as well as being in a higher risk drinking category should be considered for inclusion in future alcohol pharmacotherapy trials. (© 2026 The Author(s). Alcohol, Clinical and Experimental Research published by Wiley Periodicals LLC on behalf of Research Society on Alcohol.)
References:	Anton, R. F., S. S. O'Malley, D. A. Ciraulo, et al. 2006. “Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE Study: A Randomized Controlled Trial.” JAMA 295, no. 17: 2003–2017. Falk, D. E., S. S. O'Malley, K. Witkiewitz, et al. 2019. “Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.” JAMA Psychiatry 76, no. 4: 374–381. Falk, D. E., M. L. Ryan, J. B. Fertig, et al. 2019. “Gabapentin Enacarbil Extended‐Release for Alcohol Use Disorder: A Randomized, Double‐Blind, Placebo‐Controlled, Multisite Trial Assessing Efficacy and Safety.” Alcoholism, Clinical and Experimental Research 43, no. 1: 158–169. Fertig, J. B., M. L. Ryan, D. E. Falk, et al. 2012. “A Double‐Blind, Placebo‐Controlled Trial Assessing the Efficacy of Levetiracetam Extended‐Release in Very Heavy Drinking Alcohol‐Dependent Patients.” Alcoholism, Clinical and Experimental Research 36, no. 8: 1421–1430. Food and Drug Administration. 2025. “DDT‐COA‐000110, WHO Risk Drinking Levels of Alcohol Consumption.” U.S. Government. https://force‐dsc.my.site.com/ddt/s/ddt‐project?ddtprojectid=33. Litten, R. Z., I. J. P. Castle, D. Falk, et al. 2013. “The Placebo Effect in Clinical Trials for Alcohol Dependence: An Exploratory Analysis of 51 Naltrexone and Acamprosate Studies.” Alcoholism: Clinical and Experimental Research 37, no. 12: 2128–2137. Litten, R. Z., J. B. Fertig, D. E. Falk, et al. 2012. “A Double‐Blind, Placebo‐Controlled Trial to Assess the Efficacy of Quetiapine Fumarate XR in Very Heavy‐Drinking Alcohol‐Dependent Patients.” Alcoholism, Clinical and Experimental Research 36, no. 3: 406–416. Litten, R. Z., M. L. Ryan, J. B. Fertig, et al. 2013. “A Double‐Blind, Placebo‐Controlled Trial Assessing the Efficacy of Varenicline Tartrate for Alcohol Dependence.” Journal of Addiction Medicine 7, no. 4: 277–286. Scherrer, B., J. Guiraud, G. Addolorato, et al. 2021. “Baseline Severity and the Prediction of Placebo Response in Clinical Trials for Alcohol Dependence: A meta‐Regression Analysis to Develop an Enrichment Strategy.” Alcoholism, Clinical and Experimental Research 45, no. 9: 1722–1734. Sobell, L. C., and M. B. Sobell. 2000. “Alcohol Timeline Followback (TLFB).” In Handbook of Psychiatric Measures, 477–479. American Psychiatric Association. U.S. Food and Drug Administration. 2025. “FDA Qualifies Drug Development Tool to Facilitate Clinical Trial Research on Alcohol Use Disorder.” https://www.fda.gov/drugs/drug‐safety‐and‐availability/fda‐qualifies‐drug‐development‐tool‐facilitate‐clinical‐trial‐research‐alcohol‐use‐disorder. Witkiewitz, K., R. F. Anton, S. S. O'Malley, et al. 2025. “Reductions in World Health Organization Risk Drinking Levels as a Primary Efficacy End Point for Alcohol Clinical Trials: A Review.” JAMA Psychiatry 82: 1246–1254. Youden, W. J. 1950. “Index for Rating Diagnostic Tests.” Cancer 3, no. 1: 32–35.
Grant Information:	P50 AA010761 United States AA NIAAA NIH HHS
Contributed Indexing:	Keywords: AUD treatment; alcohol use disorder; clinical trials
Substance Nomenclature:	0 (Alcohol Deterrents)
Entry Date(s):	Date Created: 20260410 Date Completed: 20260714 Latest Revision: 20260714
Update Code:	20260715
PubMed Central ID:	PMC13066717
DOI:	10.1111/acer.70288
PMID:	41958092
Βάση Δεδομένων:	MEDLINE

Περιγραφή
ISSN:	2993-7175
DOI:	10.1111/acer.70288